About us

CNATM is on of the seven winners of the Clusters4Future initiative of the German Ministry for Education and Research (BMBF). The annual funding amounts to 5 million euro and is provided by the BMBF, the state of Bavaria an the industrial partners. The research consortium consists of research groups from the leading universities LMU and TU, researchers from the universities of Regensburg and Würzburg, as well as the Helmholtz center Munich, and 14 industrial partners from the Munich area.

A total of 22 applications were successful in obtaining funding, marking the start of the Nucleic Acid Isar Valley.

CNATM's multilateral collaborations are creating a network to develop novel nucleic acid-based agents and next-generation vaccines.

Recent discoveries give hope that the ability to design nucleic acids in a highly specific and theoretically predictable way will open up completely new therapeutic approaches in medicine and thus help many people.

There is no class of substances that is better suited for personalized medicine than nucleic acids. Our Cluster4future wants to aid nucleic acid therapies to make a breakthrough and a valuable contribution: curing people and creating jobs in and around Munich.